 Saint Herblain France, October 18 , 2021 Valneva SE Nasdaq: VALN; Euronext Paris: VLA, a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Valnevas Chief Executive Officer, Thomas Lingelbach, and the trials Chief Investigator, Adam Finn, Professor of Paediatrics at the University of Bristol, will comment on the results in a live webcast beginning at 3 p.m. CET today. Please refer to this link: 